A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
Study Purpose:
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.Disease:
Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALSStudy Type:
Interventional TrialStudy Category:
Drug TrialStudy Status:
Not enrollingPhase:
Phase IIStudy Chair(s)/Principal Investigator(s):
Merit Cudkowicz, MD (Massachusetts General Hospital)Jeremy Shefner, MD (State University of New York - Upstate Medical University)
Clinicaltrials.gov ID (11 digit #):
NCT00244244Neals Affiliated?
YesCoordinating Center Contact Information
.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address) United States